Please login to the form below
enadenotucirev
This page shows the latest enadenotucirev news and features for those working in and with pharma, biotech and healthcare.
Bristol-Myers Squibb acquires Cormorant for $520m
That project will look at the safety and efficacy of enadenotucirev - which is made by PsiOxus Therapeutics in Oxford, UK - in combination with Opdivo for the treatment of a range of
Latest news
-
BMS to explore new options for its immuno-oncology drug Opdivo
Enadenotucirev is designed to have immune stimulating effects and the companies hope that combining it with Opdivo, which alleviates immune suppression, will improve tumour shrinkage and treatment durability. ... BMS has then reserved the rights to first
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
